8-K: Cytek Biosciences Announces Preliminary 2024 Full Year Revenue, Cites Growth Despite Currency Headwinds

Cytek Biosciences reported preliminary full-year 2024 revenue between $200 million and $201 million, a 4% increase year-over-year, despite negative impacts from foreign exchange rates and some order delays.

Summary

• Cytek Biosciences announced preliminary, unaudited revenue for the full year 2024, expecting between $200 million and $201 million.
• This represents a 4% growth compared to the $193 million revenue in 2023.
• The full year revenue was negatively impacted by approximately $1 million due to foreign exchange rates.
• Fourth quarter revenue is expected to be between $57 million and $58 million.
• This represents an 11% to 13% increase compared to the third quarter of 2024.
• However, the fourth quarter revenue is down 2% to flat compared to the fourth quarter of 2023.
• The fourth quarter revenue was negatively impacted by approximately $1.5 million due to the appreciation of the US dollar.
• The company experienced order delays in some markets, which also contributed to the slightly lower than expected fourth quarter revenue.
• Cytek plans to report full financial results and provide 2025 guidance during an earnings call expected near the end of February 2025.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the overall revenue growth and strong performance in some markets, but tempered by the negative impact of currency fluctuations and order delays. The company's confidence in its long-term potential is a positive sign.

Positives

• The company achieved a 4% revenue growth for the full year 2024 compared to 2023.
• Fourth quarter revenue showed a significant increase of 11% to 13% compared to the third quarter of 2024.
• There was strong revenue growth in Asia Pacific and Rest of World markets.
• Cytek is confident in its long-term potential and business strategy.
• The company believes there is a large and growing market opportunity for its cell analysis tools.

Negatives

• The company experienced a negative foreign exchange impact of approximately $1 million on full-year revenue.
• The fourth quarter revenue was negatively impacted by approximately $1.5 million due to the appreciation of the US dollar.
• Fourth quarter revenue was slightly below expectations due to currency impacts and order delays.
• Fourth quarter revenue declined 2% to flat compared to the strong fourth quarter of 2023.

Risks

• The preliminary financial results are unaudited and subject to adjustment.
• The company is exposed to risks related to global economic, political, and market conditions.
• There is competition in the market for cell analysis tools.
• The company is dependent on certain sole and single-source suppliers.
• Cytek needs to manage the growth and complexity of its organization effectively.
• The company must manage relationships with key customers and suppliers.
• Cytek needs to retain key employees.
• The company must stay in compliance with its material contractual obligations, applicable laws, and regulations.

Future Outlook

Cytek is confident in its long-term potential and business strategy, expecting sustainable growth and profitability. The company plans to provide 2025 financial guidance during its earnings call expected near the end of February 2025.

Management Comments

• Our fourth quarter revenue was significantly higher than the prior quarters of 2024, consistent with our historical pattern, although it was slightly below expectations due to the impact of the appreciation of the US dollar against other currencies in which we do business, and order delays in some markets.
• Our revenue in Asia Pacific and Rest of World markets grew strongly.
• Despite these headwinds, we remain confident in Cyteks long-term potential and business strategy.
• There is a large and growing opportunity for our advanced cell analysis tools, and with strong execution across our portfolio, we are well positioned to deliver sustainable growth and profitability.

Industry Context

Cytek operates in the cell analysis solutions market, which is experiencing growth due to advancements in biotechnology and healthcare research. The company's focus on high-resolution, high-content, and high-sensitivity cell analysis using its patented Full Spectrum Profiling (FSP) technology positions it to compete effectively in this market.

Comparison to Industry Standards

• Cytek's 4% revenue growth is moderate compared to some high-growth biotech companies, but it is important to consider the impact of currency fluctuations.
• Companies like Bio-Rad Laboratories and Thermo Fisher Scientific, which also operate in the life sciences tools market, have reported varying growth rates, with some experiencing higher growth in specific segments.
• Cytek's focus on advanced cell analysis tools and its proprietary FSP technology differentiates it from competitors that may offer more traditional flow cytometry solutions.
• The company's performance in Asia Pacific and Rest of World markets is a positive sign, as these regions are experiencing significant growth in the life sciences sector.

Stakeholder Impact

• Shareholders will be interested in the revenue growth and future guidance.
• Employees may be impacted by the company's performance and future growth plans.
• Customers will be interested in the company's product development and market position.
• Suppliers will be impacted by the company's purchasing decisions and growth.

Next Steps

• Cytek will present at the J.P. Morgan Healthcare Conference on January 16, 2025.
• The company plans to report full financial results for the fourth quarter and full year ended December 31, 2024, and provide 2025 financial guidance during its earnings call expected near the end of February 2025.

Key Dates

Keywords

cell analysis, revenue, financial results, Cytek Biosciences, Full Spectrum Profiling, FSP, flow cytometry, biotechnology, healthcare, earnings